<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585036</url>
  </required_header>
  <id_info>
    <org_study_id>tramadol</org_study_id>
    <nct_id>NCT03585036</nct_id>
  </id_info>
  <brief_title>Oral Tramadol Versus Oral Dexketoprofen for Reducing Pain During Office Hysteroscopy</brief_title>
  <official_title>Oral Tramadol Versus Oral Dexketoprofen for Reducing Pain During Office Hysteroscopy in Post Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two hundreds and twenty five postmenopausal women undergoing outpatient hysteroscopy and
      endometrial biopsy will be randomly divided into three equal groups. To ensure blinding the
      investigators will use the double dummy technique in which group 1 will receive Tramadol
      100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo similar to
      Celecoxib, group 2 will receive dexketoprofen 25mg (neo ketadex 25, Marcryl, Egypt) in
      addition to a placebo similar to Tramadol, and group 3 will received a placebo similar to
      Tramadol and a placebo similar to Celecoxib. All drugs will be given 2 hours before the
      procedure. An independent person will generate the allocation sequence using computer
      generated random numbers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two hundreds and twenty five postmenopausal women undergoing outpatient hysteroscopy and
      endometrial biopsy will be randomly divided into three equal groups. To ensure blinding the
      investigators will use the double dummy technique in which group 1 will receive Tramadol
      100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo similar to
      Celecoxib, group 2 will receive dexketoprofen 25mg (neo ketadex 25, Marcryl, Egypt) in
      addition to a placebo similar to Tramadol, and group 3 will received a placebo similar to
      Tramadol and a placebo similar to Celecoxib. All drugs will be given 2 hours before the
      procedure. An independent person will generate the allocation sequence using computer
      generated random numbers.

      Statistics:

      Quantitative data will be statistically represented in terms of mean ± standard deviation (±
      SD) while categorical data will be represented as frequency and percentage. Comparison of
      quantitative data will be done using ANOVA test for independent samples while categorical
      data will be compared using Chi squared test or Fisher exact test when appropriate. A
      probability value (p value) less than 0.05 will be considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's perception of pain during the procedure</measure>
    <time_frame>2 minutes after starting the procedure</time_frame>
    <description>The nurse will hand the patient a VAS and the patient will mark the point corresponding to her pain.VAS of 0 indicates no pain and VAS of 10 indicates the worst possible experienced pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain after the procedure</measure>
    <time_frame>30 minutes after completing the procedure</time_frame>
    <description>The nurse will hand the patient a VAS and the patient will mark the point corresponding to her pain.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Hysteroscopy</condition>
  <arm_group>
    <arm_group_label>dexketoprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure
Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tramadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure
Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure
.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexketoprofen</intervention_name>
    <description>Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure
Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.</description>
    <arm_group_label>dexketoprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure
Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure</description>
    <arm_group_label>tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post menopausal women.

          -  vaginal bleeding.

          -  Endometrial thickness &gt;4mm.

        Exclusion Criteria:

          -  Medical disorders like uncontrolled diabetes or hypertension, cardiac, renal, liver
             disease.

          -  Gastritis or peptic ulcer.

          -  Allergy to Tramadol or dexketoprofen.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED SAMY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>lecturer in obstetrics and gynecology,cairo university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AHMED SAMY, MD</last_name>
    <phone>01100681167</phone>
    <email>ahmedsamy8233@gmail.com</email>
  </overall_contact>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>lecturer in obstetrics and gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexketoprofen trometamol</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

